These findings are indicative of the importance of hepatic miR-181a-SIRT1 in glucose and lipid metabolism and suggest that miR-181a-SIRT1 has promise as a novel target for the treatment of NAFLD. Here, SIRT1 is linked to metabolic dysfunction-associated steatotic liver disease.